Jump to content

Shuji Ogino

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Headbomb (talk | contribs) at 18:31, 4 July 2020 (→Career in MPE and colorectal cancer research: | Alter: pmc, pmid. | You can use this tool yourself. Report bugs here. | via #UCB_Gadget). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Shuji Ogino (荻野周史, Ogino Shuji, born April 24, 1968) is a molecular pathological epidemiologist, pathologist, and epidemiologist. He is currently Professor of Pathology at Harvard Medical School, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Professor in the Department of Epidemiology at Harvard T.H. Chan School of Public Health. He is also Chief of Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital,[1] and an associate member of Broad Institute of MIT and Harvard.[2] He has been known for his work on establishing a new discipline, molecular pathological epidemiology (abbreviated as MPE), which represents an interdisciplinary science of molecular pathology and epidemiology.

Education, training, and positions

Ogino graduated from University of Tokyo School of Medicine in 1993, and from University of Tokyo Graduate School of Medicine in 2001. He underwent internship at U.S. Naval Hospital Okinawa in Japan from 1994 to 1995. After coming to the United States, Ogino underwent residency training in anatomic pathology and clinical pathology at Allegheny General Hospital (Drexel University) from 1995 to 1997, and at Case Western Reserve University/University Hospitals Case Medical Center from 1997 to 1999. He underwent fellowship training in molecular pathology at University of Pennsylvania Medical Center from 1999 to 2000. After postdoctoral fellowship at University of Pennsylvania, he joined Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School as Instructor in Pathology in 2001. Ogino was promoted to Assistant Professor in 2004, to Associate Professor in 2008, and to Professor of the institutes in 2015. He received a Master of Science in Epidemiology degree from Harvard T.H. Chan School of Public Health in 2010, and then subsequently obtained a secondary faculty appointment (Associate Professor) in 2012, promoted to Professor at that school in 2015. Ogino became Chief of Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital in 2016, and an associate member of Broad Institute of MIT and Harvard in 2017.

Career in MPE and colorectal cancer research

Ogino proposed that research into molecular pathology with epidemiologic settings should be regarded as a distinct field, and used the term “Molecular Pathological Epidemiology (MPE)” in 2010.[3] Since his proposal, the MPE concept and paradigm have been in widespread use,[4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] and MPE has been a subject of international conferences such as American Association for Cancer Research (AACR),[21] Society for Epidemiologic Research (SER),[22] and the American Society of Preventive Oncology (ASPO).[23] The MPE approach aims to elucidate etiology of disease at molecular, individual, and population levels, applying molecular pathology to epidemiology. Utilizing tissue pathology resource and data within existing epidemiology studies, he has been publishing a large number of original articles proving the interrelationship between exposure to risk factors (e.g., environmental, dietary, lifestyle and genetic factors) and molecular pathologic signature of disease (e.g., PIK3CA mutation in colorectal cancer) including some of influential papers in the field,[24][25][26][27][28][29][30][31][32][33] as well as papers which have developed the concepts of MPE.[34][35][36][37][38][39][40][41] Ogino’s discoveries with the MPE approach include the interaction between aspirin use and PIK3CA mutation in colorectal cancer,[42] and the interaction between endoscopy screening and post-colonoscopy colorectal cancer with CIMP and microsatellite instability MSI.[43] He initiated the International Molecular Pathological Epidemiology (MPE) Meeting Series in 2013,[44] and has been serving as the conference chairperson. Its second and third meetings were held in Boston, in December 2014,[45][46] and May 2016,[47] respectively.

Ogino employed the MPE concept for proposing a paradigm shift in colorectal cancer research. His proposal for a transition from the two-colon concept (the proximal and distal colon)[48][49][50][51] to the colorectal continuum model[52] was supported by an observed linear relationship between the location on the colon and Microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutation frequency from the database analyses of over 1,400 colorectal cancer cases.[53] This colorectal continuum model has been supported by others.[54][55][56]

Ogino has introduced several new paradigms and research frameworks, including “the GWAS-MPE approach”,[57] “the unique tumor principal”,[58] “the unique disease principle”,[59] “the etiologic field effect model”,[60] "the integrative lifecourse epidemiology - MPE model",[61] “the pharmaco-MPE model”[62] and “the immuno-MPE model”,[63] all of which are related to the field of MPE.

Honors and awards

References

  1. ^ http://www.brighamandwomens.org/Departments_and_Services/pathology/Research/MPE.aspx?sub=8
  2. ^ https://www.broadinstitute.org/what-broad/history-leadership/founders/our-faculty-associate-members#O
  3. ^ Ogino, S; Stampfer, M (2010). "Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology". J Natl Cancer Inst. 102 (6): 365–367. doi:10.1093/jnci/djq031. PMC 2841039. PMID 20208016.
  4. ^ Curtin, Karen; Slattery, Martha L; Samowitz, Wade S (2011). "CpG Island Methylation in Colorectal Cancer: Past, Present and Future". Pathology Research International. 2011: 902674. doi:10.4061/2011/902674. PMC 3090226. PMID 21559209.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Galon, Jérôme; Pagès, Franck; Marincola, Francesco M; Angell, Helen K; Thurin, Magdalena; Lugli, Alessandro; Zlobec, Inti; Berger, Anne; Bifulco, Carlo; Botti, Gerardo; Tatangelo, Fabiana; Britten, Cedrik M; Kreiter, Sebastian; Chouchane, Lotfi; Delrio, Paolo; Arndt, Hartmann; Asslaber, Martin; Maio, Michele; Masucci, Giuseppe V; Mihm, Martin; Vidal-Vanaclocha, Fernando; Allison, James P; Gnjatic, Sacha; Hakansson, Leif; Huber, Christoph; Singh-Jasuja, Harpreet; Ottensmeier, Christian; Zwierzina, Heinz; Laghi, Luigi; et al. (2012). "Cancer classification using the Immunoscore: A worldwide task force". Journal of Translational Medicine. 10: 205. doi:10.1186/1479-5876-10-205. PMC 3554496. PMID 23034130.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. ^ Ku, Chee-Seng; Cooper, David N; Wu, Mengchu; Roukos, Dimitrios H; Pawitan, Yudi; Soong, Richie; Iacopetta, Barry (2012). "Gene discovery in familial cancer syndromes by exome sequencing: Prospects for the elucidation of familial colorectal cancer type X". Modern Pathology. 25 (8): 1055–68. doi:10.1038/modpathol.2012.62. PMID 22522846.
  7. ^ Koshiol, Jill; Lin, Shih-Wen (2012). "Can Tissue-Based Immune Markers be Used for Studying the Natural History of Cancer?". Annals of Epidemiology. 22 (7): 520–30. doi:10.1016/j.annepidem.2012.03.001. PMC 3596808. PMID 22481034.
  8. ^ Fini L, Grizzi F, Laghi L (2012). Ettarh R, ed. Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression. InTech. pp. 323–40. ISBN 9789535100621.
  9. ^ Dogan, S; Shen, R; Ang, D. C; Johnson, M. L; d'Angelo, S. P; Paik, P. K; Brzostowski, E. B; Riely, G. J; Kris, M. G; Zakowski, M. F; Ladanyi, M (2012). "Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers". Clinical Cancer Research. 18 (22): 6169–77. doi:10.1158/1078-0432.CCR-11-3265. PMC 3500422. PMID 23014527.
  10. ^ Spitz, M. R; Caporaso, N. E; Sellers, T. A (2012). "Integrative Cancer Epidemiology--The Next Generation". Cancer Discovery. 2 (12): 1087–90. doi:10.1158/2159-8290.CD-12-0424. PMC 3531829. PMID 23230187.
  11. ^ Shanmuganathan, Rajasree; Basheer, Nazeema B; Amirthalingam, Laxmi; Muthukumar, Harshiny; Kaliaperumal, Rajendran; Shanmugam, Kumaran (2013). "Conventional and Nanotechniques for DNA Methylation Profiling". The Journal of Molecular Diagnostics. 15 (1): 17–26. doi:10.1016/j.jmoldx.2012.06.007. PMID 23127612.
  12. ^ Hughes, L. A. E; Melotte, V; De Schrijver, J; De Maat, M; Smit, V. T. H. B. M; Bovee, J. V. M. G; French, P. J; Van Den Brandt, P. A; Schouten, L. J; De Meyer, T; Van Criekinge, W; Ahuja, N; Herman, J. G; Weijenberg, M. P; Van Engeland, M (2013). "The CpG Island Methylator Phenotype: What's in a Name?". Cancer Research. 73 (19): 5858–68. doi:10.1158/0008-5472.CAN-12-4306. PMID 23801749.
  13. ^ Hagland, Hanne R; Søreide, Kjetil (2015). "Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways". Cancer Letters. 356 (2): 273–80. doi:10.1016/j.canlet.2014.02.026. PMID 24614287.
  14. ^ Bishehsari, Faraz; Mahdavinia, M; Vacca, M; Malekzadeh, R; Mariani-Costantini, R (2014). "Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention". World Journal of Gastroenterology. 20 (20): 6055–72. doi:10.3748/wjg.v20.i20.6055. PMC 4033445. PMID 24876728.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ Hughes LAE, Simons CCJM, van den Brandt PA, van Engeland M, Weijenberg MP. Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Curr Colorectal Cancer Rep. 2017;13(6):455-469.
  16. ^ Rescigno, Tania; Micolucci, Luigina; Tecce, Mario; Capasso, Anna (2017). "Bioactive Nutrients and Nutrigenomics in Age-Related Diseases". Molecules. 22 (1): 105. doi:10.3390/molecules22010105. PMC 6155887. PMID 28075340.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  17. ^ Jiang, Ming-jie; Dai, Juan-Juan; Gu, Dian-na; Huang, Qian; Tian, Ling (2016). "Aspirin in pancreatic cancer: Chemopreventive effects and therapeutic potentials". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1866 (2): 163–76. doi:10.1016/j.bbcan.2016.08.002. PMID 27567928.
  18. ^ Martinez-Useros, Javier; Garcia-Foncillas, Jesus (2016). "Obesity and colorectal cancer: Molecular features of adipose tissue". Journal of Translational Medicine. 14: 21. doi:10.1186/s12967-016-0772-5. PMC 4722674. PMID 26801617.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  19. ^ Serafino, Annalucia; Sferrazza, Gianluca; Colini Baldeschi, Arianna; Nicotera, Giuseppe; Andreola, Federica; Pittaluga, Eugenia; Pierimarchi, Pasquale (2016). "Developing drugs that target the Wnt pathway: Recent approaches in cancer and neurodegenerative diseases". Expert Opinion on Drug Discovery. 12 (2): 169–186. doi:10.1080/17460441.2017.1271321. PMID 27960558. S2CID 205918130.
  20. ^ Richiardi, Lorenzo; Barone-Adesi, Francesco; Pearce, Neil (2017). "Cancer subtypes in aetiological research" (PDF). European Journal of Epidemiology. 32 (5): 353–361. doi:10.1007/s10654-017-0253-z. PMID 28497292. S2CID 3940690.
  21. ^ Ogino S. Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Cancer Prev Res (Phila). 2013;6(11 suppl):CN06-1.
  22. ^ Kuller, LH; Bracken, MB; Ogino, S; Prentice, RL; Tracy, RP (2013). "The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium". Am J Epidemiol. 178 (9): 1350–4. doi:10.1093/aje/kwt239. PMC 3988450. PMID 24105654.
  23. ^ Epplein, M; Bostick, R. M; Mu, L; Ogino, S; Braithwaite, D; Kanetsky, P. A (2014). "Challenges and Opportunities in International Molecular Cancer Prevention Research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report". Cancer Epidemiology, Biomarkers & Prevention. 23 (11): 2613–7. doi:10.1158/1055-9965.EPI-14-0848. PMC 4221505. PMID 25277796.
  24. ^ Chan, AT; Ogino, S; Fuchs, CS (2007). "Aspirin use and risk of colorectal cancer according to cyclooxygenase-2 expression". N Engl J Med. 356 (21): 2131–42. doi:10.1056/nejmoa067208. PMID 17522398.
  25. ^ Chan, AT; Ogino, S; Fuchs, CS (2009). "Aspirin use and survival after diagnosis of colorectal cancer". JAMA. 302 (6): 649–658. doi:10.1001/jama.2009.1112. PMC 2848289. PMID 19671906.
  26. ^ Morikawa, T; Kuchiba, A; Yamauchi, M; Meyerhardt, JA; Shima, K; Nosho, K; Chan, AT; Giovannucci, E; Fuchs, CS; Ogino, S (2011). "Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer". JAMA. 305 (16): 1685–1694. doi:10.1001/jama.2011.513. PMC 3087286. PMID 21521850.
  27. ^ Straussman, R; Morikawa, T; Shee, K; Barzily-Rokni, M; Qian, ZR; Du, J; Davis, A; Mongare, MM; Gould, J; Frederick, DT; Cooper, ZA; Chapman, PB; Solit, DB; Ribas, A; Lo, RS; Flaherty, KT; Ogino, S; Wargo, JA; Golub, TR (2012). "Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion". Nature. 487 (7408): 500–504. doi:10.1038/nature11183. PMC 3711467. PMID 22763439.
  28. ^ Nishihara, R; Lochhead, P; Kuchiba, A; Jung, S; Yamauchi, M; Liao, X; Imamura, Y; Qian, ZR; Morikawa, T; Wang, M; Spiegelman, D; Cho, E; Giovannucci, E; Fuchs, CS; Chan, AT; Ogino, S (2013). "Aspirin use and colorectal cancer incidence risk according to BRAF mutation status". JAMA. 309 (24): 2563–2571. doi:10.1001/jama.2013.6599. PMC 3743040. PMID 23800934.
  29. ^ Ogino, S; Liao, X; Imamura, Y; Yamauchi, M; McCleary, NJ; Ng, K; Niedzwiecki, D; Saltz, LB; Mayer, RJ; Whittom, R; Hantel, A; Benson, III AB; Mowat, RB; Spiegelman, D; Goldberg, RM; Bertagnolli, MM; Meyerhardt, JA; Fuchs, CS (2013). "Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial". J Natl Cancer Inst. 105 (23): 1789–1798. doi:10.1093/jnci/djt298. PMC 3848984. PMID 24231454.
  30. ^ Barry, ER; Morikawa, T; Butler, BL; Shrestha, K; de la Rosa, R; Yan, KS; Fuchs, CS; Magness, ST; Smits, R; Ogino, S; Kuo, CJ; Camargo, FD (2013). "Restriction of intestinal stem cell expansion and the regenerative response by YAP". Nature. 493 (7430): 106–110. Bibcode:2013Natur.493..106B. doi:10.1038/nature11693. PMC 3536889. PMID 23178811.
  31. ^ Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, Markowitz SD, Chan AT. "Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
  32. ^ Mehta, RS; Nishihara, R; Cao, Y; Song, M; Mima, K; Qian, ZR; Nowak, JA; Kosumi, K; Hamada, T; Masugi, Y; Bullman, S; Drew, DA; Kostic, AD; Fung, TT; Garrett, WS; Huttenhower, C; Wu, K; Meyerhardt, JA; Zhang, X; Willett, WC; Giovannucci, EL; Fuchs, CS; Chan, AT; Ogino, S (2017). "Dietary patterns and risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue". JAMA Oncol. 3 (7): 921–927. doi:10.1001/jamaoncol.2016.6374. PMC 5502000. PMID 28125762.
  33. ^ Hamada, T; Cao, Y; Qian, ZR; Masugi, Y; Nowak, JA; Yang, J; Song, M; Mima, K; Kosumi, K; Liu, L; Shi, Y; Silva Ad, Gu M; Li, W; Keum, N; Zhang, X; Wu, K; Meyerhardt, JA; Giovannucci, EL; Giannakis, M; Rodig, SJ; Freeman, GJ; Nevo, D; Wang, M; Chan, AT; Fuchs, CS; Nishihara, R; Ogino, S (2017). "Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status". J Clin Oncol. 35 (16): 1836–1844. doi:10.1200/jco.2016.70.7547. PMC 5455595. PMID 28406723.
  34. ^ Ogino, S; Galon, J; Fuchs, CS; Dranoff, G. "Cancer immunology – integrated analysis of host and tumor factors for personalized medicine". Nat Rev Clin Oncol. 2011 (8): 711–719.
  35. ^ Ogino, S; King, EE; Beck, AH; Sherman, ME; Milner, DA; Giovannucci, E (2012). "Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science". Am J Epidemiol. 176 (8): 659–667. doi:10.1093/aje/kws226. PMC 3571252. PMID 22935517.
  36. ^ Ogino, S; Giovannucci, E (2012). "Lifestyle factors and colorectal cancer microsatellite instability – Molecular pathological epidemiology science, based on unique tumour principle". Int J Epidemiol. 41 (4): 1072–1074. doi:10.1093/ije/dys076. PMC 3429874. PMID 22596930.
  37. ^ Ogino, S; Fuchs, CS; Giovannucci, E (2012). "How many molecular subtypes? Implications of the unique tumor principle in personalized medicine". Expert Rev Mol Diagn. 12 (6): 621–628. doi:10.1586/erm.12.46. PMC 3492839. PMID 22845482.
  38. ^ Ogino, S; Lochhead, P; Chan, AT; Nishihara, R; Cho, E; Wolpin, BM; Meyerhardt, JA; Meissner, A; Schernhammer, ES; Fuchs, CS; Giovannucci, E (2013). "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease". Modern Pathology. 26 (4): 465–84. doi:10.1038/modpathol.2012.214. PMC 3637979. PMID 23307060.
  39. ^ Field, AE; Camargo Jr, CA; Ogino (2013). "one size does not fit all". JAMA. 310 (20): 2147–2148. doi:10.1001/jama.2013.281501. PMID 24189835.
  40. ^ Ogino, S; Lochhead, P; Giovannucci, E; Meyerhardt, JA; Fuchs, CS; Chan, AT (2014). "Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology". Oncogene. 33 (23): 2949–2955. doi:10.1038/onc.2013.244. PMC 3818472. PMID 23792451.
  41. ^ Lochhead, P; Chan, AT; Giovannucci, E; Fuchs, CS; Wu, K; Nishihara, R; O'Brien, M; Ogino, S (2014). "Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions". Am J Gastroenterol. 109 (8): 1205–1214. doi:10.1038/ajg.2014.153. PMC 4125459. PMID 24935274.
  42. ^ Liao, X; Lochhead, P; Nishihara, R; Morikawa, T; Kuchiba, A; Yamauchi, M; Imamura, Y; Qian, ZR; Baba, Y; Shima, K; Sun, R; Nosho, K; Meyerhardt, JA; Giovannucci, E; Fuchs, CS; Chan, AT; Ogino, S (2012). "Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival". N Engl J Med. 367 (17): 1596–1606. doi:10.1056/NEJMoa1207756. PMC 3532946. PMID 23094721.
  43. ^ Nishihara, R; Wu, K; Lochhead, P; Morikawa, T; Liao, X; Qian, ZR; Inamura, K; Kim, SA; Kuchiba, A; Yamauchi, M; Imamura, Y; Willett, WC; Rosner, BA; Fuchs, CS; Giovannucci, E; Ogino, S; Chan, AT (2013). "Long-term colorectal-cancer incidence and mortality after lower endoscopy". N Engl J Med. 369 (12): 1095–1105. doi:10.1056/nejmoa1301969. PMC 3840160. PMID 24047059.
  44. ^ "Home | International Molecular Pathological Epidemiology Meeting".
  45. ^ The Ogino MPE lab ( http://ogino-mpe-lab.dana-farber.org )
  46. ^ Ogino, Shuji; Campbell, Peter T; Nishihara, Reiko; Phipps, Amanda I; Beck, Andrew H; Sherman, Mark E; Chan, Andrew T; Troester, Melissa A; Bass, Adam J; Fitzgerald, Kathryn C; Irizarry, Rafael A; Kelsey, Karl T; Nan, Hongmei; Peters, Ulrike; Poole, Elizabeth M; Qian, Zhi Rong; Tamimi, Rulla M; Tchetgen Tchetgen, Eric J; Tworoger, Shelley S; Zhang, Xuehong; Giovannucci, Edward L; Van Den Brandt, Piet A; Rosner, Bernard A; Wang, Molin; Chatterjee, Nilanjan; Begg, Colin B (2015). "Proceedings of the second international molecular pathological epidemiology (MPE) meeting". Cancer Causes & Control. 26 (7): 959–72. doi:10.1007/s10552-015-0596-2. PMC 4466011. PMID 25956270.
  47. ^ Campbell, Peter T; Rebbeck, Timothy R; Nishihara, Reiko; Beck, Andrew H; Begg, Colin B; Bogdanov, Alexei A; Cao, Yin; Coleman, Helen G; Freeman, Gordon J; Heng, Yujing J; Huttenhower, Curtis; Irizarry, Rafael A; Kip, N. Sertac; Michor, Franziska; Nevo, Daniel; Peters, Ulrike; Phipps, Amanda I; Poole, Elizabeth M; Qian, Zhi Rong; Quackenbush, John; Robins, Harlan; Rogan, Peter K; Slattery, Martha L; Smith-Warner, Stephanie A; Song, Mingyang; Vanderweele, Tyler J; Xia, Daniel; Zabor, Emily C; Zhang, Xuehong; et al. (2017). "Proceedings of the third international molecular pathological epidemiology (MPE) meeting". Cancer Causes & Control. 28 (2): 167–176. doi:10.1007/s10552-016-0845-z. PMC 5303153. PMID 28097472.
  48. ^ Iacopetta, Barry (2002). "Are there two sides to colorectal cancer?". International Journal of Cancer. 101 (5): 403–8. doi:10.1002/ijc.10635. PMID 12216066.
  49. ^ Gervaz, Pascal; Bucher, Pascal; Morel, Philippe (2004). "Two colons-two cancers: Paradigm shift and clinical implications". Journal of Surgical Oncology. 88 (4): 261–6. doi:10.1002/jso.20156. PMID 15565587.
  50. ^ Carethers, John M (2011). "One Colon Lumen but Two Organs". Gastroenterology. 141 (2): 411–2. doi:10.1053/j.gastro.2011.06.029. PMC 3424279. PMID 21708155.
  51. ^ Albuquerque, Cristina; Bakker, Elvira R.M; Van Veelen, Wendy; Smits, Ron (2011). "Colorectal cancers choosing sides". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1816 (2): 219–31. doi:10.1016/j.bbcan.2011.07.005. PMID 21855610.
  52. ^ Papagiorgis, Petros (2013). "Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both: Table 1". Gut. 62 (10): 1519–20. doi:10.1136/gutjnl-2013-305209. PMID 23749607. S2CID 390756.
  53. ^ Yamauchi, Mai; Morikawa, Teppei; Kuchiba, Aya; Imamura, Yu; Qian, Zhi Rong; Nishihara, Reiko; Liao, Xiaoyun; Waldron, Levi; Hoshida, Yujin; Huttenhower, Curtis; Chan, Andrew T; Giovannucci, Edward; Fuchs, Charles; Ogino, Shuji (2012). "Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum". Gut. 61 (6): 847–54. doi:10.1136/gutjnl-2011-300865. PMC 3345105. PMID 22427238.
  54. ^ Jess, Per; Hansen, Iben Onsberg; Gamborg, Michael; Jess, Tine (2013). "A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer". BMJ Open. 3 (5): e002608. doi:10.1136/bmjopen-2013-002608. PMC 3657647. PMID 23793665.
  55. ^ Papagiorgis, Petros (2013). "Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both: Table 1". Gut. 62 (10): 1519–20. doi:10.1136/gutjnl-2013-305209. PMID 23749607. S2CID 390756.
  56. ^ Loree, Jonathan M; Pereira, Allan A.L; Lam, Michael; Willauer, Alexandra N; Raghav, Kanwal; Dasari, Arvind; Morris, Van. K; Advani, Shailesh; Menter, David G; Eng, Cathy; Shaw, Kenna; Broaddus, Russell; Routbort, Mark J; Liu, Yusha; Morris, Jeffrey S; Luthra, Rajyalakshmi; Meric-Bernstam, Funda; Overman, Michael J; Maru, Dipen; Kopetz, Scott (2018). "Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes". Clinical Cancer Research. 24 (5): 1062–1072. doi:10.1158/1078-0432.CCR-17-2484. PMC 5844818. PMID 29180604.
  57. ^ Ogino, S; Chan, A. T; Fuchs, C. S; Giovannucci, E (2010). "Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field". Gut. 60 (3): 397–411. doi:10.1136/gut.2010.217182. PMC 3040598. PMID 21036793.
  58. ^ Ogino, Shuji; Fuchs, Charles S; Giovannucci, Edward (2014). "How many molecular subtypes? Implications of the unique tumor principle in personalized medicine". Expert Review of Molecular Diagnostics. 12 (6): 621–8. doi:10.1586/erm.12.46. PMC 3492839. PMID 22845482.
  59. ^ Ogino, Shuji; Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko; Cho, Eunyoung; Wolpin, Brian M; Meyerhardt, Jeffrey A; Meissner, Alexander; Schernhammer, Eva S; Fuchs, Charles S; Giovannucci, Edward (2013). "Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host and disease". Modern Pathology. 26 (4): 465–84. doi:10.1038/modpathol.2012.214. PMC 3637979. PMID 23307060..
  60. ^ Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko; Fuchs, Charles S; Beck, Andrew H; Giovannucci, Edward; Ogino, Shuji (2014). "Etiologic field effect: Reappraisal of the field effect concept in cancer predisposition and progression". Modern Pathology. 28 (1): 14–29. doi:10.1038/modpathol.2014.81. PMC 4265316. PMID 24925058.
  61. ^ Nishi, A; Kawachi, I; Koenen, KC; Wu, K; Nishihara, R; Ogino, S (2015). "Lifecourse epidemiology and molecular pathological epidemiology". Am J Prev Med. 48 (1): 116–119. doi:10.1016/j.amepre.2014.09.031. PMC 4274745. PMID 25528613.
  62. ^ Ogino, Shuji; Jhun, Iny; Mata, Douglas A; Soong, Thing Rinda; Hamada, Tsuyoshi; Liu, Li; Nishihara, Reiko; Giannakis, Marios; Cao, Yin; Manson, Joann E; Nowak, Jonathan A; Chan, Andrew T (2017). "Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology". NPJ Precision Oncology. 1. doi:10.1038/s41698-017-0042-x. PMC 5856171. PMID 29552640.
  63. ^ Ogino, S; Nishihara, R; VanderWeele, TJ; Wang, M; Nishi, A; Lochhead, P; Qian, ZR; Zhang, X; Wu, K; Nan, H; Yoshida, K; Milner, DA; Chan, AT; Field, AE; Camargo, CA; Williams, MA; Giovannucci, EL (2016). "The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine". Epidemiology. 27 (4): 602–611. doi:10.1097/ede.0000000000000471. PMC 4892980. PMID 26928707.
  64. ^ The world’s Most Influential Minds:2014 ("Archived copy". Archived from the original on 2014-10-07. Retrieved 2014-10-09.{{cite web}}: CS1 maint: archived copy as title (link)) Thomson Reuter. Retrieved September 5, 2014.
  65. ^ http://www.faseb.org/About-FASEB/Who-We-Are/Governance/Board-Ordinary-Committees.aspx Retrieved September 15, 2014.
  66. ^ Ogino, Shuji. "Accelerating Transdisciplinary Epidemiology of Colorectal Cancer". Grantome.
  67. ^ Highly Cited Researchers 2015 (http://highlycited.com/#ogino)
  68. ^ https://clarivate.com/hcr/researchers-list/archived-lists/
  69. ^ https://clarivate.com/hcr/2017-researchers-list/#freeText%3DOgino
  70. ^ "Awards - ASIP 2018 Annual Meeting".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Shuji_Ogino&oldid=966006056"